mvf-her-2(628-647)-crl 1005 vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2000 (NCT00017537)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mvf-her-2(628-647)-crl 1005 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00017537 | Phase 1 | Mar 1, 2000 | National Cancer Institute (NCI), University of Alabama, Birmingham |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2000 |
2 organizations
Page 1 / 1